Japanese researchers have announced that they have decided to transplant brain stem-derived pluripotent stem cells (iPS) from patients with Parkinson's disease. The world's first trial.
Kyoto University Team 2.4 million iPS cell infusion – capable of producing all types of cells – Surgery in the left part of the brain for 3 hours in October.
A statement from the University of Kyoto said that a 50-year-old man will be in good health and under surveillance for two years.
If problems occur within the next six months, the researchers will insert 2.4 million additional cells into the right side of the brain.
Healthy donor iPS cells are supposed to develop into neurons that produce dopamine, a neurotransmitter involved in exercise regulation.
Kyoto University in July Clinical trial with 7 patients Between 50 and 69 years old.
That Parkinson's disease is characterized by degeneration of nerve cells, Symptoms such as tremors, muscle rigidity, and loss of ability to move the body gradually worsen.
Read here: Parkinson 's may have originated in the appendix
It affects more than 10 million people in the world.According to the US Parkinson's disease base. has exist Colombia has over 220,000 people with this disease.According to the Colombian Association of Neurology, currently available therapies "improve symptoms without slowing the progression of the disease.
The new investigation is to reverse the evil. before In clinical trials, experiments were conducted on monkeys with human-derived stem cells Can improve the ability of primates to suffer from some form of Parkinson's disease, according to a report in the journal Science.
The survival level of the transplanted cells for 2 years was closely monitored by injecting into the primate brain and no tumor was found.
Induced pluripotent stem cells (iPS) produce four genes by virtue of reducing embryonic adult cells to embryonic states (usually inactive in adults). This genetic manipulation returns the ability to produce certain cells depending on where they are implanted.
The use of iPS cells does not cause serious ethical problems unlike stem cells from human embryos.